Measurement of Specific IgG Antibody Levels in Serum of Patients on Regimes Comprising High Total Dose Beta-Lactam Therapy

1986 ◽  
Vol 79 (4) ◽  
pp. 344-348 ◽  
Author(s):  
D. Lee ◽  
Janet M. Dewdney ◽  
R.G. Edwards ◽  
K.A. Neftel ◽  
M. Wälti
Keyword(s):  
Total Dose ◽  
Beta Lactam ◽  
Igg Antibody ◽  
Specific Igg ◽  
Antibody Levels ◽  
High Total Dose

IgG Levels after Treatment with Antigen Vials Based on the Scratch Testing, Intradermal Testing, Modified RAST Testing

1986 ◽  
Vol 95 (3_part_1) ◽  
pp. 307-311 ◽  
Author(s):  
Richard J. Trevino
Keyword(s):  
Scratch Testing ◽  
Igg Antibody ◽  
Intradermal Testing ◽  
Blocking Antibody ◽  
Multiple Treatment ◽  
End Point ◽  
Specific Igg ◽  
Inhalant Allergens ◽  
Inhalant Allergy ◽  
Antibody Levels

In this study, there were three groups of patients—each group consisting of four patients. The first group had been skin tested by the scratch method, the second group was skin tested by the end point titration intradermal method, and the third group had been tested for inhalant allergy by the modified RAST technique. All of them had multiple treatment vials made, dependent on the type of testing they had, and the vials all included the ten inhalants that were tested for. All patients had been treated for a year with weekly immunotherapy injections. Specific IgG levels, blocking antibody levels to the ten inhalant allergens, were determined. The results were that the patients who had been scratch tested had the lowest levels of specific IgG blocking antibody—while both intradermal end point titration and modified RAST testing had much higher elevations of blocking IgG antibody, with the RAST having the highest. It is concluded that, since the treatment vials prepared after scratch testing of all the antigens are at the same concentration, there are many antigens that are not given in adequate amounts to cause a good IgG response whereas, by calibrating the concentrations of antigens in the intradermal titration and the modified RAST testing, all the antigens are being injected in sufficient quantities to get a good blocking antibody response.

scholarly journals Lymphocyte Subsets and Specific IgG Antibody Levels in Clindamycin-Treated and Untreated Dogs Experimentally Infected with Babesia gibsoni

2003 ◽  
Vol 65 (5) ◽  
pp. 579-584 ◽  
Author(s):  
Retno WULANSARI ◽  
Agus WIJAYA ◽  
Hitoshi ANO ◽  
Yoichiro HORII ◽  
Susumu MAKIMURA
Keyword(s):  
Lymphocyte Subsets ◽  
Babesia Gibsoni ◽  
Igg Antibody ◽  
Specific Igg ◽  
Antibody Levels

scholarly journals Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine

Vaccines ◽  
2018 ◽  
Vol 6 (4) ◽  
pp. 82 ◽  
Author(s):  
Els van Westen ◽  
Mirjam Knol ◽  
Alienke Wijmenga-Monsuur ◽  
Irina Tcherniaeva ◽  
Leo Schouls ◽  
...  
Keyword(s):  
Pneumococcal Vaccine ◽  
Pneumococcal Disease ◽  
Booster Dose ◽  
Multiple Time ◽  
Igg Antibody ◽  
Primary Series ◽  
Specific Igg ◽  
Multiple Time Points ◽  
Antibody Levels ◽  
Antibody Kinetics

The two currently available ten- and thirteen-valent pneumococcal conjugate vaccines (PCV10 and PCV13) both induce serotype-specific IgG anti-polysaccharide antibodies and are effective in preventing vaccine serotype induced invasive pneumococcal disease (IPD) as well as in reducing overall vaccine-serotype carriage and transmission and thereby inducing herd protection in the whole population. IgG levels decline after vaccination and could become too low to prevent carriage acquisition and/or pneumococcal disease. We compared the levels of 10-valent (PCV10) and 13-valent (PCV13) pneumococcal vaccine induced serum IgG antibodies at multiple time points after primary vaccinations. Data from two separate studies both performed in the Netherlands in infants vaccinated at 2, 3, and 4 months of age with either PCV10 or PCV13 were compared. Antibody levels were measured at 5, 8, and 11 months of age, during the interval between the primary immunization series and the 11-months booster dose. Serotype-specific IgG levels were determined by multiplex immunoassay. Although antibody kinetics showed significant variation between serotypes and between vaccines for the majority of the 10 shared serotypes, i.e., 1, 5, 7F, 9V, 14, 18C, and 23F, antibody concentrations were sufficiently high for both vaccines, immediately after the primary series and throughout the whole period until the booster dose. In contrast, for serotypes 4 and 19F in the PCV10 group and for serotypes 4 and 6B in the PCV13 group, IgG antibody concentrations already come within reach of the frequently used seroprotection level of 0.35 μg/mL immediately after the primary series at the five month time point and/or at eight months. This paper addresses the importance of revealing differences in serotype-specific and pneumococcal vaccine-dependent IgG antibody patterns during the interval between the primary series and the booster dose, an age period with a high IPD incidence. Trial registration: www.trialregister.nl NTR3069 and NTR2316.

scholarly journals Immunogenicity of 10-valent pneumococcal conjugate vaccine among infants attending Mbagathi District Hospital, Kenya

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 165
Author(s):  
Michael Walekhwa ◽  
Margaret Muturi ◽  
Elizabeth Bukusi
Keyword(s):  
Chronic Illness ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
District Hospital ◽  
Maternal Diet ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Specific Igg ◽  
Socio Demographic Factors ◽  
Antibody Levels

Introduction: This study aimed to determine the serum concentration of IgG antibodies as an indicator of immunogenicity, alongside the assessment of socio-demographic factors that affect IgG antibody levels in infants immunized with 10-valent pneumococcal conjugate vaccine (PCV-10) at the Mbagathi District Hospital in Kenya.Materials and methods: This cross-sectional study measured serum IgG antibodies among infants who had completed a 3-dose course of PCV-10. IgG antibodies to pneumococcal serotype-specific capsular polysaccharide were measured through enzyme-linked immunosorbent assay (ELISA).Results: The majority (83%) of infants who completed the required dose of pneumococcal conjugate vaccine had serum titres of pneumococcal disease- (PD) specific IgG antibodies of between 0.34 mg/dl and 0.36 mg/dl. 4% of infants had serum titres of 0.30 mg/dl to 0.33 mg/dl. The remaining 2% had IgG antibody titres of either ≤0.25 mg/dl, or between 0.25 mg/dl to 0.29 mg/dl. Additionally, there was multi-collinearity among the IgG antibody levels of the infants studied and several variables that had an effect on these levels. These included: alcohol consumption by infants’ biological mothers during pregnancy (r =.595, p ≤ 0.05); maternal diet during pregnancy (r =.137, p ≤ 0.05); breastfeeding frequency (r =.220, p ≤ 0.05); proximity to other children (r =.133, p ≤ 0.05); child hospitalization (r =.131, p ≤ 0.05) and chronic illness (r =.154, p ≤0.01).Conclusion: PCV-10 is immunogenic against PD four weeks after completion of 3-doses among the infants attending the Child Welfare clinic at the Mbagathi District Hospital in Kenya. Socio-demographic factors which include consumption of alcoholic drinks by infant’s biological mother during pregnancy and study infant chronic illness negatively affect the development of PD specific IgG. A balanced maternal diet during pregnancy and a breastfeeding frequency superior to three times per day have a significant positive effect on serum pneumococcal IgG levels among infants.

scholarly journals Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood

2011 ◽  
Vol 127 (6) ◽  
pp. 1480-1485 ◽  
Author(s):  
Adnan Custovic ◽  
Lars Soderstrom ◽  
Staffan Ahlstedt ◽  
Peter D. Sly ◽  
Angela Simpson ◽  
...  
Keyword(s):  
Specific Ige ◽  
Igg Antibody ◽  
Specific Igg ◽  
Antibody Levels ◽  
The Relationship

scholarly journals Seroprevalence of Aspergillus-Specific IgG Antibody among Mozambican Tuberculosis Patients

2021 ◽  
Vol 7 (8) ◽  
pp. 595
Author(s):  
Helmut J. F. Salzer ◽  
Isabel Massango ◽  
Nilesh Bhatt ◽  
Emelva Machonisse ◽  
Maja Reimann ◽  
...  
Keyword(s):  
Antibody Level ◽  
Hiv Positive ◽  
Igg Antibody ◽  
Tuberculosis Patients ◽  
Tb Treatment ◽  
Life Threatening ◽  
Specific Igg ◽  
Limited Health ◽  
Antibody Levels ◽  
Hiv Negative

Background: Chronic pulmonary aspergillosis (CPA) is a life-threatening sequel in patients with pulmonary tuberculosis (PTB). Aspergillus-specific IgG antibody is a useful diagnostic biomarker supporting CPA diagnosis, especially in countries with limited health recourses. Methods: We conducted a prospective pilot study to assess the seroprevalence of Aspergillus-specific IgG antibodies among 61 Mozambican tuberculosis patients before, during, and after the end of TB treatment. Aspergillus-specific IgG antibody levels were measured using the ImmunoCAP®. Results: In this study, 3 out of 21 HIV-negative PTB patients had a positive Aspergillus-specific IgG antibody level before, during, and after the end of TB treatment. Antibody levels were 41.1, 45.5, and 174 mg/L at end of treatment (EOT), respectively. Additionally, two HIV-negative PTB patients with negative Aspergillus-specific IgG antibody levels at baseline became seropositive at EOT (41.9 and 158 mg/L, respectively). Interestingly, none of the HIV-positive PTB patients (40/61) had a positive Aspergillus-specific IgG antibody level at any time, neither at baseline nor at EOT. Probable CPA was diagnosed in one HIV-negative patient (5%; 1/20). Conclusion: Seroprevalence of Aspergillus-specific IgG antibody may differ between HIV-negative and HIV-positive Mozambican PTB patients. Future studies evaluating post-tuberculosis lung disease should integrate CPA as a life-threatening sequel to PTB.

scholarly journals Sensitization with Eustrongylides sp. (Nematoda: Dioctophymatidae) antigens induce production of specific IgG and IgE in murine model

2021 ◽  
Vol 30 (1) ◽  
Author(s):  
Bianca Porto Kuraiem ◽  
Maurício Afonso Verícimo ◽  
Marcelo Knoff ◽  
Danuza Pinheiro Bastos Garcia de Mattos ◽  
Sérgio Carmona de São Clemente
Keyword(s):  
Cellular Immunity ◽  
Saline Solution ◽  
Gradual Increase ◽  
Igg Antibody ◽  
Human Diet ◽  
Allergenic Potential ◽  
Specific Igg ◽  
Epicutaneous Sensitization ◽  
Antibody Levels ◽  
First Time

Abstract Fish consumption plays an important role in human diet. Hoplias malabaricus, commonly known as traíra, is a freshwater fish widely appreciated in several Brazilian states and frequently infected by Eustrongylides sp. fourth-instar larvae (L4). The aim of the present study was to evaluate allergenic potential of Eustrongylides sp. L4 crude extract (CEE). BALB/c mice were immunized intraperitoneally (IP) by 10 μg CEE with 2 mg of aluminum hydroxide on days 0 and 35. Specific IgG and IgE antibody levels were determined after immunization and cellular immunity was evaluated by assessing intradermal reaction in ear pavilion. Epicutaneous sensitization was performed in dorsal region by antigen exposure using a Finn-type chamber containing 50 μg of CEE or saline solution, followed by evaluation of specific antibody levels. IP immunization resulted in a gradual increase in IgG antibody levels and transitory IgE production. Significant increase in ear thickness was observed in cellular hypersensitivity reaction. In case of antigen exposure by epicutaneous route, CEE was able to induce meaningfully increased levels of specific IgG and IgE antibodies as well as heightened cellular immunity. Both intraperitoneal immunization and epicutaneous contact with Eustrongylides sp. larval antigens were observed for first time to be capable of inducing immunological sensitization in mice.

scholarly journals Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for IgG antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay

2020 ◽  
Author(s):  
Joachim Marien ◽  
Johan Michiels ◽  
Leo Heyndrickx ◽  
Karen Kerkhof ◽  
Nikki Foque ◽  
...  
Keyword(s):  
Large Scale ◽  
Detection Threshold ◽  
Neutralizing Antibody ◽  
Cost Effective ◽  
Antibody Detection ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Serological Tests ◽  
Specific Igg ◽  
Antibody Levels

Large-scale serosurveillance of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) will only be possible if serological tests are sufficiently reliable, rapid and inexpensive. Current assays are either labour-intensive and require specialised facilities (e.g. virus neutralization assays), or expensive with suboptimal specificity (e.g. commercial ELISAs). Bead-based assays offer a cost-effective alternative and allow for multiplexing to test for antibodies of other pathogens. Here, we compare the performance of four antigens for the detection of SARS-CoV-2 specific IgG antibodies in a panel of sera that includes both severe (n=40) and mild (n=52) cases, using a neutralization and a Luminex bead-based assay. While we show that neutralising antibody levels are significantly lower in mild than in severe cases, we demonstrate that a combination of recombinant nucleocapsid protein (NP), receptor-binding domain (RBD) and the whole spike protein (S1S2) results in a highly sensitive (96%) and specific (99%) bead-based assay that can detect IgG antibodies in both groups. Although S1-specific IgG levels correlate most strongly with neutralizing antibody levels, they fall below the detection threshold in 10% of the cases in our Luminex assay. In conclusion, our data supports the use of RBD, NP and S1S2 for the development of SARS-CoV-2 serological bead-based assays. Finally, we argue that low antibody levels in mild/asymptomatic cases might complicate the epidemiological assessment of large-scale surveillance studies.

scholarly journals Robust immune response to the BNT162b mRNA vaccine in an elderly population vaccinated 15 months after recovery from COVID-19

2021 ◽  
Author(s):  
Hye Kyung Lee ◽  
Ludwig Knabl ◽  
Ludwig Knabl ◽  
Sebastian Kapferer ◽  
Birgit Pateter ◽  
...  
Keyword(s):  
Immune Response ◽  
Booster Vaccination ◽  
The Elderly ◽  
High Risk Population ◽  
Igg Antibody ◽  
Robust Immune Response ◽  
Additional Cell ◽  
Specific Igg ◽  
Antibody Levels ◽  
The Impact

AbstractKnowledge about the impact of prior SARS-CoV-2 infection of the elderly on mRNA vaccination response is needed to appropriately address the need for booster vaccination in this vulnerable population. To address this, we investigated antibody and genomic immune responses in 16 elderly (avg. 81 yrs.) individuals that had received a single booster dose of BNT162b vaccine 15 months after recovering from COVID-19. Spike-specific IgG antibody levels increased in each of the study participants from an average of 710 U/ml prior to the vaccination to more than 40,000 U/ml within ten weeks after the vaccination. In contrast, anti-spike-specific IgG antibody levels averaged 2,190 U/ml in 14 healthy SARS-CoV-2-naïve individuals (avg. 58 yrs.) ten weeks after the second dose of BNT162b. RNA-seq conducted on PBMCs demonstrated the activation of interferon-activated genetic programs in both cohorts within one day. Unlike their transient induction in the younger naïve population, persistent activity and the initiation of additional cell cycle regulated programs were obtained in the older COVID-19 recovered population. Here we show that the elderly, a high-risk population, can mount a strong antibody and a persistent molecular immune response upon receiving a single dose of mRNA vaccine 15 months after recovery from COVID-19.

Sign in / Sign up

Export Citation Format

Share Document